Stockwatch: Lilly And GW Move Goalposts
This article was originally published in Scrip
Executive Summary
There were few bright spots last week in life sciences, with the NASDAQ Biotech Index finishing down by 4% as it continued, uncharacteristically, to underperform the broad S&P 500 index. The handful of positive announcements from the industry actually look very fragile on closer inspection, perhaps marking new lows for an industry where the integrity of clinical trial announcements and investment bank analysis can no longer be believed in.
You may also be interested in...
Stockwatch: The TIGER That Came To Lilly
The reasons behind Lilly's latest clinical failure had much less to do with the indication and more to do with repeating the past mistakes of Inspire and Sunesis. Unfortunately, that same die has already been cast for the trials of Biogen and Ophthotech that are due to report imminently.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.